Literature DB >> 9032180

Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum.

R Louis1, J Shute, S Biagi, L Stanciu, F Marrelli, H Tenor, R Hidi, R Djukanović.   

Abstract

We have applied the technique of sputum induction by hypertonic saline in asthmatics and nonatopic control subjects to study an array of indices of airway inflammation believed to be relevant to asthma pathogenesis. Compatible with a central role for eosinophils and mast cells in asthma, sputum of asthmatic subjects contained increased numbers of eosinophils and levels of eosinophil cationic protein (ECP) and mast cell tryptase. Eosinophil numbers, and ECP and histamine levels correlated with the degree of methacholine airways responsiveness, and ECP, tryptase, and histamine correlated with raised concentrations of albumin. Using the micro-Boyden chamber technique eosinophil chemotactic activity was identified only in the sputum from asthmatics. The correlation between the raised levels of total IgA, IL-8/IgA complexes, and tryptase and the degree of sputum eosinophilia and ECP levels, suggests possible mechanisms for eosinophil chemotaxis and activation in asthma. Row cytometric analysis of sputum lymphocytes showed an increase in CD4+ T cells and T cells expressing intercellular adhesion molecule-1 (ICAM-1) in asthma which, together with the finding of raised levels of soluble ICAM-1 in the sputum, indicates upregulation of this adhesion molecule. Finally, the proportion of CD16+ natural killer (NK) cells was reduced in the sputum of asthmatics. These observations highlight the importance of the airway inflammation in causing asthma and further confirm the usefulness of sputum induction as a tool in asthma research.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032180     DOI: 10.1164/ajrccm.155.2.9032180

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

1.  Sputum T lymphocytes in asthma, COPD and healthy subjects have the phenotype of activated intraepithelial T cells (CD69+ CD103+).

Authors:  M J Leckie; G R Jenkins; J Khan; S J Smith; C Walker; P J Barnes; T T Hansel
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

2.  Cytokine production from sputum cells in eosinophilic versus non-eosinophilic asthmatics.

Authors:  V Quaedvlieg; M Henket; J Sele; R Louis
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Authors:  Shailendra R Singh; Nikol Sullo; Maria Matteis; Giuseppe Spaziano; John McDonald; Ruth Saunders; Lucy Woodman; Konrad Urbanek; Antonella De Angelis; Raffaele De Palma; Rachid Berair; Mitesh Pancholi; Vijay Mistry; Francesco Rossi; Remo Guerrini; Girolamo Calò; Bruno D'Agostino; Christopher E Brightling; David G Lambert
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

4.  Methodology for Sputum Induction and Laboratory Processing.

Authors:  Julien Guiot; Sophie Demarche; Monique Henket; Virginie Paulus; Sophie Graff; Florence Schleich; Jean-Louis Corhay; Renaud Louis; Catherine Moermans
Journal:  J Vis Exp       Date:  2017-12-17       Impact factor: 1.355

5.  Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation.

Authors:  G T De Sanctis; J A MacLean; S Qin; W W Wolyniec; H Grasemann; C N Yandava; A Jiao; T Noonan; J Stein-Streilein; F H Green; J M Drazen
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

Review 6.  Biomarkers in the Management of Difficult Asthma.

Authors:  Florence Schleich; Sophie Demarche; Renaud Louis
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

7.  Sputum Inflammometry to Manage Chronic Obstructive Pulmonary Disease Exacerbations: Beyond Guidelines.

Authors:  Carmen Venegas; Nan Zhao; Terence Ho; Parameswaran Nair
Journal:  Tuberc Respir Dis (Seoul)       Date:  2020-06-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.